1700010L13Rik Activators
1700010L13Rik Activators encompass a set of chemical compounds that facilitate the functional enhancement of the protein 1700010L13Rik through various intracellular signaling pathways. Compounds such as Forskolin and Epigallocatechin gallate (EGCG) play pivotal roles in this enhancement, with Forskolin increasing intracellular cAMP levels, thus activating PKA which may phosphorylate components within the pathways involving 1700010L13Rik. EGCG, through its inhibition of certain tyrosine kinases, may alleviate competitive signaling and foster a conducive environment for the activation of 1700010L13Rik. Additionally,1700010L13Rik Activators encompass a set of chemical compounds that facilitate the functional enhancement of the protein 1700010L13Rik through various intracellular signaling pathways. Compounds such as Forskolin and Epigallocatechin gallate (EGCG) play pivotal roles in this enhancement, with Forskolin increasing intracellular cAMP levels, thus activating PKA which may phosphorylate components within the pathways involving 1700010L13Rik. EGCG, through its inhibition of certain tyrosine kinases, may alleviate competitive signaling and foster a conducive environment for the activation of 1700010L13Rik. Additionally, phospholipid-derived activator Sphingosine-1-phosphate and the calcium ionophores Ionomycin and A23187 manipulate lipid signaling and calcium levels, respectively, processes that can activate calcium-dependent proteins and pathways associated with 1700010L13Rik.
Furthermore, the modulation of protein kinase C by PMA and alteration of the PI3K pathway by inhibitors such as LY294002 and Wortmannin are critical in the selective activation of pathways that may involve 1700010L13Rik. The inhibition of key signaling nodes by compounds like SB203580, U0126, and Genistein can shift cellular signaling dynamics, potentially enhancing the activity of 1700010L13Rik by favoring its associated pathways. Thapsigargin, by raising intracellular calcium, contributes to this collective activation by stimulating calcium-dependent signaling mechanisms. Collectively, these activators operate through strategic intervention in signaling cascades, thereby influencing the functional activity of 1700010L13Rik without the need for upregulation at the transcriptional or translational level, ensuring a targeted approach to protein activation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC). If RIKEN's activity is modulated by PKC, the activation of this kinase by PMA can enhance RIKEN's function through phosphorylation or other regulatory mechanisms associated with PKC signaling. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that raises intracellular calcium levels, potentially affecting proteins regulated by calcium-dependent signaling. If RIKEN is influenced by such signaling, ionomycin can indirectly enhance its activity through calcium-mediated pathways. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
This lipid signaling molecule activates sphingosine-1-phosphate receptors, potentially influencing cellular pathways involving RIKEN. If RIKEN is part of sphingolipid-mediated signaling, sphingosine-1-phosphate could enhance its function through this pathway. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is known to inhibit certain protein kinases. If RIKEN is negatively regulated by these kinases, EGCG could enhance RIKEN activity by lifting this inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
This compound is a phosphoinositide 3-kinase (PI3K) inhibitor. If RIKEN is part of the PI3K/Akt signaling pathway, inhibition of PI3K by LY294002 could result in altered signaling that indirectly enhances RIKEN's function. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is another calcium ionophore. By increasing intracellular calcium levels, it can activate calcium-dependent signaling pathways that could enhance the function of RIKEN if it is regulated by calcium signaling. | ||||||
Adenosine 3′,5′-cyclic monophosphate | 60-92-4 | sc-217584 sc-217584A sc-217584B sc-217584C sc-217584D sc-217584E | 100 mg 250 mg 5 g 10 g 25 g 50 g | $116.00 $179.00 $265.00 $369.00 $629.00 $1150.00 | ||
db-cAMP is a cAMP analog that can permeate cell membranes and activate PKA intracellularly. If RIKEN's activity is modulated by cAMP levels and PKA, db-cAMP can serve as a direct enhancer of RIKEN by mimicking cAMP's effect. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor. If specific protein kinases negatively regulate RIKEN, inhibition by staurosporine could lift this regulation and enhance the activity of RIKEN. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. If RIKEN is part of a signaling pathway that is suppressed by p38 MAPK, SB203580 could enhance RIKEN's activity by inhibiting p38 MAPK. | ||||||